866-997-4948(US-Canada Toll Free)

Hyperlipidemia Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Apr 2013

Category :

Metabolic Disorders

No. of Pages : 99 Pages


Global Markets Directs, \'Hyperlipidemia Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hyperlipidemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hyperlipidemia. 

Hyperlipidemia Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Hyperlipidemia.
  • A review of the Hyperlipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Hyperlipidemia pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Hyperlipidemia.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Hyperlipidemia pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Hyperlipidemia Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Hyperlipidemia 10
Hyperlipidemia Therapeutics under Development by Companies 12
Hyperlipidemia Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Hyperlipidemia Therapeutics – Products under Development by Companies 20
Hyperlipidemia Therapeutics – Products under Investigation by Universities/Institutes 22
Companies Involved in Hyperlipidemia Therapeutics Development 23
Amgen Inc. 23
Eli Lilly and Company 24
Isis Pharmaceuticals, Inc. 25
Merck & Co., Inc. 26
Daewoong Pharmaceutical Co., Ltd. 27
Dr. Reddy\'s Laboratories Limited 28
Aegerion Pharmaceuticals, Inc. 29
Idera Pharmaceuticals, Inc. 30
Yuhan Corporation 31
WhanIn Pharmaceutical Co., Ltd. 32
Immuron Limited 33
Hanall Pharmaceutical Co., Ltd. 34
Ahn-Gook Pharmaceutical Co., Ltd. 35
aRigen Pharmaceuticals, Inc. 36
Esperion Therapeutics, Inc. 37
FORMAC Pharmaceuticals N.V. 38
Hyperlipidemia – Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Combination Products 40
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
IMO-3100 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
IMD-4 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
DRL-17822 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
(atorvastatin calcium + losartan potassium) - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
(atorvastatin calcium + losartan potassium) - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ARMAK-105 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ETC-1002 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
YH-16410 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
(atorvastatin + aspirin) - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
(ezetimibe + atorvastatin calcium) - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
(simvastatin Immediate Release + amlodipine maleate Delayed Release) - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
(simvastatin Immediate Release + amlodipine maleate Delayed Release) - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
AMG-145 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
(irbesartan + atorvastatin calcium) - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
ARBs + Statins - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
IMM-124E - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
LY-3015014 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
JCH-2 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
(irbesartan + atorvastatin calcium) - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
HCP-1007 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
WIB-901H - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
CideB Antisense Oligonucleotide - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
AGSAA-010 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
XAF-5 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
fenofibrate Formulated With Mesoporous Silica - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
(rosuvastatin + amlodipine) - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Hyperlipidemia Therapeutics – Drug Profile Updates 77
Hyperlipidemia Therapeutics – Discontinued Products 87
Hyperlipidemia Therapeutics - Dormant Products 88
Hyperlipidemia – Product Development Milestones 92
Featured News & Press Releases 92
Nov 05, 2012: Roche\'s Dalcetrapib Increases HDL Levels But Fails To Reduce Risk Of Cardiovascular Events, Study Finds 92
Sep 28, 2012: Pronova And Takeda Announce New Drug Application Approval For Lotriga 2g In Japan For Treatment Of Hyperlipidemia 93
Aug 13, 2012: Ranbaxy Shifts Production Of Generic Lipitor To Mohali, India 93
Apr 27, 2012: Merck Wins US Zetia/Vytorin Patent Infringement Lawsuit 93
Apr 13, 2012: HanAll BioPharma Initiates Phase I And III Trials Of HL040 94
Mar 19, 2012: Pronova And Takeda Announce Results From Phase III Trial Of TAK-085 At Japanese Circulation Society 94
Jan 25, 2012: FDA Does Not Approve New Indications For ZETIA 95
Sep 29, 2011: Pronova And Takeda Announce Submission Of New Drug Application For TAK-085 In Japan For Treatment Of Hyperlipidemia 95
Jul 25, 2011: Daiichi Sankyo Receives FDA Approval For Welchol sNDA 96
Jul 18, 2011: Kowa And Lilly Report New Study Results Showing Minimal Potential For Drug Interaction Between LIVALO And Common Antiretroviral Therapy 96

Appendix 98
Methodology 98
Coverage 98
Secondary Research 98
Primary Research 98
Expert Panel Validation 98
Contact Us 99
Disclaimer 99

List of Table


Number of Products Under Development for Hyperlipidemia, H1 2013 10
Products under Development for Hyperlipidemia Comparative Analysis, H1 2013 11
Number of Products under Development by Companies, H1 2013 13
Number of Products under Development by Companies, H1 2013 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2013 15
Comparative Analysis by Late Stage Development, H1 2013 16
Comparative Analysis by Mid Clinical Stage Development, H1 2013 17
Comparative Analysis by Early Clinical Stage Development, H1 2013 18
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 19
Products under Development by Companies, H1 2013 20
Products under Development by Companies, H1 2013 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2013 22
Amgen Inc., H1 2013 23
Eli Lilly and Company, H1 2013 24
Isis Pharmaceuticals, Inc., H1 2013 25
Merck & Co., Inc., H1 2013 26
Daewoong Pharmaceutical Co., Ltd., H1 2013 27
Dr. Reddy\'s Laboratories Limited, H1 2013 28
Aegerion Pharmaceuticals, Inc., H1 2013 29
Idera Pharmaceuticals, Inc., H1 2013 30
Yuhan Corporation, H1 2013 31
WhanIn Pharmaceutical Co., Ltd., H1 2013 32
Immuron Limited, H1 2013 33
Hanall Pharmaceutical Co., Ltd., H1 2013 34
Ahn-Gook Pharmaceutical Co., Ltd., H1 2013 35
aRigen Pharmaceuticals, Inc., H1 2013 36
Esperion Therapeutics, Inc., H1 2013 37
FORMAC Pharmaceuticals N.V., H1 2013 38
Assessment by Monotherapy Products, H1 2013 39
Assessment by Combination Products, H1 2013 40
Assessment by Stage and Route of Administration, H1 2013 42
Assessment by Stage and Molecule Type, H1 2013 44
Hyperlipidemia Therapeutics Drug Profile Updates 77
Hyperlipidemia Therapeutics Discontinued Products 87
Hyperlipidemia Therapeutics Dormant Products 88
Hyperlipidemia Therapeutics Dormant Products (Contd..1) 89
Hyperlipidemia Therapeutics Dormant Products (Contd..2) 90
Hyperlipidemia Therapeutics Dormant Products (Contd..3) 91

List of Chart


Number of Products under Development for Hyperlipidemia, H1 2013 10
Products under Development for Hyperlipidemia Comparative Analysis, H1 2013 11
Products under Development by Companies, H1 2013 12
Products under Investigation by Universities/Institutes, H1 2013 15
Late Stage Products, H1 2013 16
Mid Clinical Stage Products, H1 2013 17
Early Clinical Stage Products, H1 2013 18
Discovery and Pre-Clinical Stage Products, H1 2013 19
Assessment by Monotherapy Products, H1 2013 39
Assessment by Combination Products, H1 2013 40
Assessment by Route of Administration, H1 2013 41
Assessment by Stage and Route of Administration, H1 2013 42
Assessment by Molecule Type, H1 2013 43
Assessment by Stage and Molecule Type, H1 2013 44

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *